149 related articles for article (PubMed ID: 37506533)
21. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
22. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Gynecol Oncol; 2016 Jun; 141(3):447-453. PubMed ID: 27072806
[TBL] [Abstract][Full Text] [Related]
23. OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma.
An Y; Wang Q; Sun F; Zhang G; Wang F; Zhang L; Li Y; Ren W; Zhu W; Li Y; Ji S; Guo X
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899312
[TBL] [Abstract][Full Text] [Related]
24. The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
de Jong JM; Hoogendam JP; Braat AJAT; Zweemer RP; Gerestein CG
Gynecol Oncol; 2021 Aug; 162(2):517-525. PubMed ID: 34053747
[TBL] [Abstract][Full Text] [Related]
25. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
26. Is minimally invasive surgery for clinical stage I uterine carcinosarcoma safe?
Sinha R; Nizam A; Shan W; Shih KK; Frimer M; Sakaris A; Goldberg GL
J Robot Surg; 2022 Aug; 16(4):943-949. PubMed ID: 34716874
[TBL] [Abstract][Full Text] [Related]
27. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Surg Oncol; 2018 Sep; 27(3):433-440. PubMed ID: 30217299
[TBL] [Abstract][Full Text] [Related]
28. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
30. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
Bax HJ; Chauhan J; Stavraka C; Santaolalla A; Osborn G; Khiabany A; Grandits M; López-Abente J; Palhares LCGF; Chan Wah Hak C; Robinson A; Pope A; Woodman N; Naceur-Lombardelli C; Malas S; Coumbe JEM; Nakamura M; Laddach R; Mele S; Crescioli S; Black AM; Lombardi S; Canevari S; Figini M; Sayasneh A; Tsoka S; FitzGerald K; Gillett C; Pinder S; Van Hemelrijck M; Kristeleit R; Ghosh S; Montes A; Spicer J; Karagiannis SN; Josephs DH
Br J Cancer; 2023 Jan; 128(2):342-353. PubMed ID: 36402875
[TBL] [Abstract][Full Text] [Related]
31. The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma.
Menczer J; Elyashiv O; Ben-Shem E; Peled O; Levy T
Isr Med Assoc J; 2018 Apr; 20(4):213-216. PubMed ID: 29629727
[TBL] [Abstract][Full Text] [Related]
32. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance.
D'Angelica M; Ammori J; Gonen M; Klimstra DS; Low PS; Murphy L; Weiser MR; Paty PB; Fong Y; Dematteo RP; Allen P; Jarnagin WR; Shia J
Mod Pathol; 2011 Sep; 24(9):1221-8. PubMed ID: 21572402
[TBL] [Abstract][Full Text] [Related]
33. Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma.
Richmond AM; Blake EA; Torkko K; Smith EE; Spillman MA; Post MD
Int J Gynecol Cancer; 2017 Nov; 27(9):1895-1903. PubMed ID: 28704324
[TBL] [Abstract][Full Text] [Related]
34. Uterine carcinosarcoma: A review of the literature.
Cantrell LA; Blank SV; Duska LR
Gynecol Oncol; 2015 Jun; 137(3):581-8. PubMed ID: 25805398
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract][Full Text] [Related]
36. Uterine carcinosarcoma: a primer for radiologists.
Ravishankar P; Smith DA; Avril S; Kikano E; Ramaiya NH
Abdom Radiol (NY); 2019 Aug; 44(8):2874-2885. PubMed ID: 31030248
[TBL] [Abstract][Full Text] [Related]
37. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Stockhammer P; Okumus Ö; Hegedus L; Rittler D; Ploenes T; Herold T; Kalbourtzis S; Bankfalvi A; Sucker A; Kimmig R; Aigner C; Hegedus B
Pathol Oncol Res; 2021; 27():636088. PubMed ID: 34257602
[No Abstract] [Full Text] [Related]
38. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
[TBL] [Abstract][Full Text] [Related]
39. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
40. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Enomoto T; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Surg Oncol; 2018 Sep; 25(9):2756-2766. PubMed ID: 29971677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]